Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical
Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the l...
2018-02-25
文传商讯
AstraZeneca to Present Transformative Data at ESMO Asia 2017 Congress f
Phase III FLAURA data, including new data in patients with CNS metastases, c...
2017-11-21
文传商讯
Boehringer Ingelheim: Advancing anticoagulation care with new data at E
New data to be presented will inform physicians on different aspects of trea...
2017-08-22
文传商讯
Boehringer Ingelheim Phase III study now enrolling patients with progre
For the first time, patients with different fibrosing lung diseases will be ...
2017-03-22
文传商讯
Faslodex Demonstrates Progression-Free Survival Advantage in 1st Line A
Faslodex reduces risk of progression by 20% and extends median progression-f...
2016-10-11
文传商讯
Boehringer Ingelheim launches ambitious ELUXA trial programme to broadl
Comprehensive ELUXA trial programme explores olmutinib* (BI 1482694) as a mo...
2016-06-04
文传商讯
LUME-Meso trial enrols first patient: Boehringer Ingelheim’s new pivot
The trial will evaluate efficacy and safety of nintedanib* as a first-line o...
2016-05-11
文传商讯
